Cargando…

Production of Recombinant Anti-Cancer Vaccines in Plants

Plant expression systems have been developed to produce anti-cancer vaccines. Plants have several advantages as bioreactors for the production of subunit vaccines: they are considered safe, and may be used to produce recombinant proteins at low production cost. However, several technical issues hind...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jeong Hwan, Ko, Kisung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499611/
https://www.ncbi.nlm.nih.gov/pubmed/28554196
http://dx.doi.org/10.4062/biomolther.2016.126
_version_ 1783248502442164224
author Lee, Jeong Hwan
Ko, Kisung
author_facet Lee, Jeong Hwan
Ko, Kisung
author_sort Lee, Jeong Hwan
collection PubMed
description Plant expression systems have been developed to produce anti-cancer vaccines. Plants have several advantages as bioreactors for the production of subunit vaccines: they are considered safe, and may be used to produce recombinant proteins at low production cost. However, several technical issues hinder large-scale production of anti-cancer vaccines in plants. The present review covers design strategies to enhance the immunogenicity and therapeutic potency of anti-cancer vaccines, methods to increase vaccine-expressing plant biomass, and challenges facing the production of anti-cancer vaccines in plants. Specifically, the issues such as low expression levels and plant-specific glycosylation are described, along with their potential solutions.
format Online
Article
Text
id pubmed-5499611
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Society of Applied Pharmacology
record_format MEDLINE/PubMed
spelling pubmed-54996112017-07-09 Production of Recombinant Anti-Cancer Vaccines in Plants Lee, Jeong Hwan Ko, Kisung Biomol Ther (Seoul) Review Plant expression systems have been developed to produce anti-cancer vaccines. Plants have several advantages as bioreactors for the production of subunit vaccines: they are considered safe, and may be used to produce recombinant proteins at low production cost. However, several technical issues hinder large-scale production of anti-cancer vaccines in plants. The present review covers design strategies to enhance the immunogenicity and therapeutic potency of anti-cancer vaccines, methods to increase vaccine-expressing plant biomass, and challenges facing the production of anti-cancer vaccines in plants. Specifically, the issues such as low expression levels and plant-specific glycosylation are described, along with their potential solutions. The Korean Society of Applied Pharmacology 2017-07 2017-05-30 /pmc/articles/PMC5499611/ /pubmed/28554196 http://dx.doi.org/10.4062/biomolther.2016.126 Text en Copyright ©2017, The Korean Society of Applied Pharmacology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lee, Jeong Hwan
Ko, Kisung
Production of Recombinant Anti-Cancer Vaccines in Plants
title Production of Recombinant Anti-Cancer Vaccines in Plants
title_full Production of Recombinant Anti-Cancer Vaccines in Plants
title_fullStr Production of Recombinant Anti-Cancer Vaccines in Plants
title_full_unstemmed Production of Recombinant Anti-Cancer Vaccines in Plants
title_short Production of Recombinant Anti-Cancer Vaccines in Plants
title_sort production of recombinant anti-cancer vaccines in plants
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499611/
https://www.ncbi.nlm.nih.gov/pubmed/28554196
http://dx.doi.org/10.4062/biomolther.2016.126
work_keys_str_mv AT leejeonghwan productionofrecombinantanticancervaccinesinplants
AT kokisung productionofrecombinantanticancervaccinesinplants